The Central Government through a notice on April 02, 2007 has set off the Patent Appellate Board. As a transitional arrangement, appeals with regard to patentability were taken up by the High Courts. However after the notification all appeals pending before the High Courts will be transferred to the Patent Appellate Board. Following the notice the Madras High Court ordered the transfer of the Novartis case relating to the rejection of patent application for anti cancer drug Gleevec to the Patent Appellate Board. The patentabilty aspect of the application will be decided by the Appellate Board while the issue relating to Constitutionality will be decided by the High  Court.

InfoLogix, Inc has acquired from DDMS Holdings, LLC a patent portfolio relating to RFID technology that manages proper medication and delivery.

The acquired technology will help doctors, patients and pharmaceutical companies to track, trace and monitor drug information down to the individual pill level throughout the supply chain. It can track the medication as well as sense conditions within and around the medication container including the removal of the pill from it and exposure to changes like heat, moisture or light. Whenever a change appears a signal will be sent to a mobile RFID device which will help doctors and other health employees to monitor the administration of medication ensuring compliance with label instruction. This technology will not only be of help in hospitals and clinical trials but also for self-dosing by patients.